CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / October 12, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to announce the following update with its M2MMA division:
M2MMA, the latest division of M2BIO Sciences, has officially confirmed its first two promotional events, which will take place in the picturesque setting of Phuket, Thailand. The first event is scheduled for late March 2024 at the iconic Sinbi Boxing Stadium, followed by the second in late May 2024. These promotions will feature undercard and main card events, offering a thrilling combination of Muay Thai and MMA, all sanctioned by the esteemed World Muay Thai Organisation (WMO).
M2MMA is strategically aligning itself with the 6th International and Thai Martial Arts Games (ITMA Games), which host a wide range of martial arts competitions, including Muay Thai, kickboxing, boxing, karate, BJJ, dap thai (Thai sword), muay boran, and amateur MMA, all sanctioned by renowned international martial arts organizations. The ITMA Games will be held at Saphan Hin Stadium two weeks before M2MMA's first promotional event in March. Martial arts enthusiasts mark your calendars, as March promises to be a month filled with exciting action.
Following the thrilling bouts in Thailand, M2MMA will host its next set in Pretoria, South Africa, with events scheduled for late July and September. The season finale will unfold in the dazzling city of Dubai in October and November.
"I am thrilled to see this come to fruition and to witness M2MMA excel in combat sports. As the executive assistant for the ITMA Games and the WMO, I extend my full support and gratitude to M2MMA for allowing me to be part of this revolutionary mixed martial arts organization." - Jade Sirisompan.
M2MMA is not just another player in the world of MMA; it is an innovative and disruptive division of M2BIO with a clear vision to revolutionize the world of mixed martial arts (MMA) by placing their athletes' well-being and long-term health at the forefront. Jeff Robinson, the visionary behind M2MMA, states, "We are committed to transforming the industry standard by pioneering a new era of fighter care that extends far beyond the ring."
M2MMA will also introduce the use of Artificial Intelligence (AI) in a groundbreaking fashion. Robinson says, "We are going to go ballistic." With this technology, viewers will have access to real-time data and metrics, offering unprecedented insight into the action inside the ring. You'll be able to see the real-time physiological condition of each athlete, the force of each blow, the impact of each strike, and so much more.
In addition, M2BIO Sciences proudly announces the appointment of Victor Lange as CEO of M2MMA. Lange, with a rich history in the world of sports, including studying in the US and earning his playing rights on the PGA Tour for several years, has since been deeply involved in the fitness and business world. Lange is enthusiastic about his role and affirms, "I'm unbelievably proud and honored to lead M2BIO's revolutionary new M2MMA division. Our fights will be exclusive, our fighters will receive the best treatment, and we will entertain viewers like never before. MMA is a sport that includes high-level problem-solving with dire physical consequences. M2MMA will provide the means and care to showcase that to its fullest potential.''
For comprehensive insights into our company and our foray into fitness innovation, M2BIO Sciences cordially invites you to explore our official website. Watch for forthcoming events and disclosures as we navigate this groundbreaking fusion of MMA and the scientific realm. M2MMA's commitment to athlete welfare, technological innovation, and global expansion promises an exciting future for both fighters and fans of mixed martial arts.
About Institute of Biomedical Research Corp./ DBA M2Bio Sciences
Institute of Biomedical Research Corp is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids, medical psilocybin and mental health therapeutic research powered by artificial intelligence, and evidence-based sustainable products and solutions that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, Liviana™ brands as well as artificial intelligence-powered nutrition products and solutions under the M2Biome brand. In addition, our research and clinical trials with psilocybin are aimed at new therapies to help patients suffering from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies such as artificial intelligence.
The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "MRES".
Publicly traded Company (OTC Pink: MRES)
www.m2bio.co
[email protected]
+27 72 333 2148
Find M2Bio™ on social media
Facebook:M2Bio
Instagram:M2bio.Sciences
LinkedIn:M2Bio
Twitter:@M2bio
Forward-Looking Statements
Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences to include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency, and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.
SOURCE: Institute of BioMedical Research Corp.